9 enrolling by invitation. 9 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Enrolling by invitation 9 |
| Phase 3 | 4 | Enrolling by invitation 4 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 30 | 2021-08-24 | 2025-05-04 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) ASTX727 - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Enrolling by invitation | Taiho Oncology, Inc. | 332 | 2019-09-30 | 2026-07-28 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children CliniMacs TCR alpha-beta-Biotin system - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 50 | 2015-10-01 | 2025-05-04 |
Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (3) · Neoplasm, Residual (2) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Promyelocytic, Acute (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Leukemia (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Marrow Diseases (3) · Neoplastic Processes (3) · Disease Attributes (2) · Chronic Disease (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1)
Azacitidine (2) · Induction Chemotherapy (2) · Opiate Substitution Treatment (2) · Cytarabine (1) · Homoharringtonine (1) · Lisaftoclax (1) · decitabine and cedazuridine drug combination (1) · ruxolitinib (1) · venetoclax (1)
First Affiliated Hospital of Zhejiang University (2) · Guangdong Second Provincial General Hospital (2) · Michael Pulsipher (2) · Ryvu Therapeutics SA (1) · Taiho Oncology, Inc. (1) · The First Affiliated Hospital of Soochow University (1)
China (5) · United States (3) · France (2) · Poland (2) · Armenia (1) · Austria (1) · Bulgaria (1) · Canada (1) · Germany (1) · Hungary (1) · Italy (1) · Romania (1) · Slovakia (1) · Spain (1)
Guopan Yu, PhD (1) · Michael L Pulsipher, MD (1) · Michael Pulsipher, MD (1)
2018 (1), 2025 (1)